마이코플라스마 검사 시장 - 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of mycoplasma testing Market

The global mycoplasma testing market was valued at USD 972.3 million in 2025. The market is projected to grow to USD 1,021.10 million in 2026 and further reach USD 1,551.70 million by 2034, registering a CAGR of 5.40% during the forecast period (2026-2034).

North America dominated the market with a 49.20% share in 2025, supported by strong research infrastructure, rising regulatory initiatives, and high R&D expenditure.

Mycoplasma are the smallest free-living organisms and are among the most common contaminants in cell cultures and biopharmaceutical production. Due to their lack of a rigid cell wall, they are resistant to many antibiotics and can pass through standard filtration systems. This makes routine mycoplasma testing essential in research laboratories, vaccine production, and biologics manufacturing to prevent contamination and financial losses.

COVID-19 Impact

The COVID-19 pandemic positively impacted the market due to increased storage and testing of cell cultures for vaccine and drug development. The surge in vaccine R&D significantly increased demand for testing kits and reagents in 2020. Although demand normalized in 2021, continued R&D activities for chronic diseases and infectious conditions are expected to support steady market growth through 2034.

Market Trends

Increasing Strategic Partnerships

Rising demand for advanced testing technologies has led to increased collaborations among diagnostic companies. Market players are focusing on mergers, acquisitions, and partnerships to combine expertise and enhance product portfolios. Technological advancements aimed at reducing turnaround time and improving sensitivity are gaining traction among pharmaceutical and biotechnology companies.

Technological Advancements in PCR-Based Testing

PCR-based testing methods are becoming more popular due to their high sensitivity, specificity, and faster results. Adoption of nucleic acid amplification techniques (NAT) and regulatory guideline updates are further accelerating the use of advanced testing solutions.

Market Growth Drivers

The increasing R&D expenditure among biopharmaceutical and biotechnology companies is a major driver. Growing investments in vaccine development, cell therapies, and biologics require strict contamination control measures, boosting demand for testing kits.

Rising healthcare expenditure globally and growing awareness regarding cell culture contamination are further contributing to market growth. Updated regulatory standards and quality control guidelines are encouraging routine testing in laboratories and research facilities.

Restraining Factors

High costs associated with advanced testing kits and instruments may limit adoption in emerging markets. PCR-based kits and detection systems require specialized equipment and trained professionals, increasing overall operational costs. Additionally, the shortage of skilled laboratory personnel globally may hinder market expansion in certain regions.

Segmentation Analysis

By Product

The market is segmented into reagents & kits and instruments.

• The reagents & kits segment dominated the market with a 57.85% share in 2026, driven by their frequent usage in routine laboratory testing and rising product launches.
• The instruments segment is expected to grow steadily due to increasing penetration in emerging markets and technological advancements.

By Testing Method

The market is categorized into PCR-based, culture-based, and others.

• The PCR-based segment is projected to lead with a 56.92% share in 2026, owing to high sensitivity, efficiency, and shorter turnaround time.
• The culture-based segment is expected to grow at a slower rate due to longer processing time and lower sensitivity, although its lower cost supports adoption in developing regions.

By Application

Applications include cell culture, vaccine testing, virus testing, and others.

• The cell culture segment will account for 37.36% share in 2026, supported by rising contamination concerns and increasing research activities.
• The virus testing segment is anticipated to register the highest CAGR through 2034 due to increasing outbreak monitoring.
• Vaccine testing continues to benefit from growing immunization programs and R&D investments.

By End-user

The market is segmented into biopharmaceutical & biotechnology companies, cell banks, CROs & CMOs, and others.

• The biopharmaceutical & biotechnology companies segment is projected to lead with a 32.99% share, driven by expanding R&D pipelines.
• The cell banks segment is expected to register the highest CAGR due to growing storage of stem cells and other biological samples.

Regional Insights

North America

North America remains the dominant region. The market in the region reached USD 503.2 million in 2026, with the U.S. market estimated at USD 459.6 million in 2026. Strong government funding and vaccine development initiatives continue to drive demand.

Europe

Europe is expected to grow at a moderate rate. The UK market is projected to reach USD 49.3 million by 2026, while Germany is estimated at USD 37.7 million in 2026, supported by rising R&D investments.

Asia Pacific

Asia Pacific is projected to register the highest CAGR through 2034. Japan is estimated to reach USD 52.4 million by 2026, China USD 42.3 million, and India USD 37.8 million, driven by increasing collaborations and expanding biopharmaceutical sectors.

Competitive Landscape

The market is fragmented, with key players including Merck KGaA, Thermo Fisher Scientific Inc., Lonza, F. Hoffmann-La Roche Ltd., Sartorius AG, bioMerieux SA, and Asahi Kasei Corporation.

Companies are focusing on technological innovation, product launches, partnerships, and facility expansions to strengthen their global presence. Strategic initiatives and R&D investments are expected to intensify competition through 2034.

Conclusion

The global mycoplasma testing market is projected to grow from USD 972.3 million in 2025 to USD 1,551.70 million by 2034, driven by rising R&D activities, increasing contamination concerns, and technological advancements in PCR-based testing. While high costs and skilled workforce shortages may restrain growth in emerging markets, expanding vaccine production, biologics development, and regulatory compliance requirements will sustain long-term market expansion. North America will continue to dominate, while Asia Pacific is expected to witness the fastest growth through 2034.

Segmentation By Testing Method

• PCR-based
• Culture-based
• Others

By Product

• Instruments
• Reagents & Kits

By Application

• Cell Culture
• Vaccine Testing
• Virus Testing
• Others

By End-user

• Biopharmaceutical & Biotechnology Companies
• Cell banks
• Contract Research Organizations & Contract Manufacturing Organizations
• Others

By Region

• North America (By Testing Method, Product, Application, End-user, and By Country)
  • U.S. (By Testing Method)
  • Canada (By Testing Method)
• Europe (By Testing Method, Product, Application, End-user, and Country/Sub-region)
  • U.K. (By Testing Method)
  • Germany (By Testing Method)
  • France (By Testing Method)
  • Italy (By Testing Method)
  • Spain (By Testing Method)
  • Rest of Europe (By Testing Method)
• Asia Pacific (By Testing Method, Product, Application, End-user, and Country/Sub-region)
  • China (By Testing Method)
  • Japan (By Testing Method)
  • India (By Testing Method)
  • Australia (By Testing Method)
  • Southeast Asia (By Testing Method)
  • Rest of Asia Pacific (By Testing Method)
• Rest of the World (By Testing Method, Product, Application, and End-user)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview of R&D Expenditure, Key Regions/Key Countries, 2025
• 4.2. Technological Advancements in Mycoplasma Testing
• 4.3. Key Industry Developments - Mergers, Acquisitions & Partnership
• 4.4. New Product Launches
• 4.5. Impact of COVID-19 on the Market

5. Global Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Testing Method
  • 5.1.1. PCR-based
  • 5.1.2. Culture-based
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Product
  • 5.2.1. Instruments
  • 5.2.2. Reagents & Kits
• 5.3. Market Analysis, Insights and Forecast - By Application
  • 5.3.1. Cell Culture
  • 5.3.2. Vaccine Testing
  • 5.3.3. Virus Testing
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Biopharmaceutical & Biotechnology Companies
  • 5.4.2. Cell banks
  • 5.4.3. Contract Research Organizations & Contract Manufacturing Organizations
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Rest of the World

6. North America Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Testing Method
  • 6.1.1. PCR-based
  • 6.1.2. Culture-based
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Product
  • 6.2.1. Instruments
  • 6.2.2. Reagents & Kits
• 6.3. Market Analysis, Insights and Forecast - By Application
  • 6.3.1. Cell Culture
  • 6.3.2. Vaccine Testing
  • 6.3.3. Virus Testing
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Biopharmaceutical & Biotechnology Companies
  • 6.4.2. Cell banks
  • 6.4.3. Contract Research Organizations & Contract Manufacturing Organizations
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 6.5.1. U.S.
    • 6.5.1.1. By Testing Method
  • 6.5.2. Canada
    • 6.5.2.1. By Testing Method

7. Europe Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Testing Method
  • 7.1.1. PCR-based
  • 7.1.2. Culture-based
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Product
  • 7.2.1. Instruments
  • 7.2.2. Reagents & Kits
• 7.3. Market Analysis, Insights and Forecast - By Application
  • 7.3.1. Cell Culture
  • 7.3.2. Vaccine Testing
  • 7.3.3. Virus Testing
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Biopharmaceutical & Biotechnology Companies
  • 7.4.2. Cell banks
  • 7.4.3. Contract Research Organizations & Contract Manufacturing Organizations
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.5.1. U.K
    • 7.5.1.1. By Testing Method
  • 7.5.2. Germany
    • 7.5.2.1. By Testing Method
  • 7.5.3. France
    • 7.5.3.1. By Testing Method
  • 7.5.4. Spain
    • 7.5.4.1. By Testing Method
  • 7.5.5. Italy
    • 7.5.5.1. By Testing Method
  • 7.5.6. Rest of Europe
    • 7.5.6.1. By Testing Method

8. Asia Pacific Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Testing Method
  • 8.1.1. PCR-based
  • 8.1.2. Culture-based
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Product
  • 8.2.1. Instruments
  • 8.2.2. Reagents & Kits
• 8.3. Market Analysis, Insights and Forecast - By Application
  • 8.3.1. Cell Culture
  • 8.3.2. Vaccine Testing
  • 8.3.3. Virus Testing
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Biopharmaceutical & Biotechnology Companies
  • 8.4.2. Cell banks
  • 8.4.3. Contract Research Organizations & Contract Manufacturing Organizations
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.5.1. Japan
    • 8.5.1.1. By Testing Method
  • 8.5.2. China
    • 8.5.2.1. By Testing Method
  • 8.5.3. India
    • 8.5.3.1. By Testing Method
  • 8.5.4. Australia
    • 8.5.4.1. By Testing Method
  • 8.5.5. Southeast Asia
    • 8.5.5.1. By Testing Method
  • 8.5.6. Rest of Asia Pacific
    • 8.5.6.1. By Testing Method

9. Rest of the World Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Testing Method
  • 9.1.1. PCR-based
  • 9.1.2. Culture-based
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Product
  • 9.2.1. Instruments
  • 9.2.2. Reagents & Kits
• 9.3. Market Analysis, Insights and Forecast - By Application
  • 9.3.1. Cell Culture
  • 9.3.2. Vaccine Testing
  • 9.3.3. Virus Testing
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Biopharmaceutical & Biotechnology Companies
  • 9.4.2. Cell banks
  • 9.4.3. Contract Research Organizations & Contract Manufacturing Organizations
  • 9.4.4. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Merck KGaA
    • 10.2.1.1. Overview
    • 10.2.1.2. Product
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. financials (Based on Availability)
  • 10.2.2. Thermo Fisher Scientific Inc.
    • 10.2.2.1. Overview
    • 10.2.2.2. Product
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. financials (Based on Availability)
  • 10.2.3. F. Hoffmann-La Roche Ltd.
    • 10.2.3.1. Overview
    • 10.2.3.2. Product
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. financials (Based on Availability)
  • 10.2.4. Sartorius AG
    • 10.2.4.1. Overview
    • 10.2.4.2. Product
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. financials (Based on Availability)
  • 10.2.5. Asahi Kasei Corporation
    • 10.2.5.1. Overview
    • 10.2.5.2. Product
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. financials (Based on Availability)
  • 10.2.6. Biomeriux SA
    • 10.2.6.1. Overview
    • 10.2.6.2. Product
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. financials (Based on Availability)
  • 10.2.7. Charles River Laboratories
    • 10.2.7.1. Overview
    • 10.2.7.2. Product
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. financials (Based on Availability)
  • 10.2.8. ATCC
    • 10.2.8.1. Overview
    • 10.2.8.2. Product
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. financials (Based on Availability)
  • 10.2.9. Other Prominent Players